EW
Edwards Lifesciences Corporation · Healthcare · Medical - Devices
Señales de momentum (gestores comparables):
amplitud de titulares +5.0% ·
flujo de acciones +12.6% ·
nuevas posiciones netas +4.8%
· fórmula
Acumulación amplia: acciones en aumento entre más titulares
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q4 2024
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 14.87M | $1.28B | n/a | n/a |
| Q2 2026 | 165 | -6 | 426.19M | $38.48B | +2 | −7 |
| Q1 2026 | 173 | +2 | 408.99M | $32.75B | +6 | −5 |
| Q4 2025 | 170 | 0 | 441.50M | $37.63B | +2 | −1 |
| Q3 2025 | 24 | -1 | 280.60M | $21.82B | +1 | −3 |
| Q2 2025 | 23 | 0 | 232.09M | $18.15B | n/a | n/a |
| Q1 2025 | 20 | -1 | 112.98M | $8.18B | n/a | −1 |
| Q4 2024 | 21 | +1 | 116.40M | $8.61B | +1 | n/a |
| Q3 2024 | 19 | +1 | 77.58M | $5.12B | +2 | −1 |
| Q2 2024 | 18 | n/a | 60.09M | $5.55B | n/a | n/a |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 33.21M | +5.3% | $2.46B | 0.5% | ▲ Add | 3 | SEC ↗ ×9 |
| 2 | State Street Global Advisors ✦ (pasivo) | 25.81M | n/a | $1.91B | 0.1% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (pasivo) | 13.65M | +0.9% | $1.01B | 0.1% | ▲ Add | 3 | SEC ↗ ×2 |
| 4 | Fisher Asset Management ✦ | 9.78M | +7.7% | $723.66M | 0.3% | ▲ Add | 3 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 9.42M | +372.9% | $697.22M | 0.7% | ▲ Add | 3 | SEC ↗ ×2 |
| 6 | Norges Bank ✦ (pasivo) | 8.25M | +14.3% | $610.90M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 7 | Marshall Wace ✦ | 5.81M | +55.7% | $430.37M | 0.5% | ▲ Add | 3 | SEC ↗ ×3 |
| 8 | T. Rowe Price ✦ | 3.30M | -6.9% | $244.13M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 9 | PRIMECAP Management ✦ | 2.04M | +14.5% | $151.28M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 10 | Adage Capital Partners ✦ | 1.22M | +46.6% | $90.60M | 0.2% | ▲ Add | 3 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 976.82K | -0.7% | $72.31M | 0.1% | ▼ Trim | 3 | SEC ↗ ×2 |
| 12 | Baillie Gifford ✦ | 706.80K | +238.7% | $52.32M | 0.0% | ▲ Add | 3 | SEC ↗ ×4 |
| 13 | Renaissance Technologies ✦ | 652.49K | -46.6% | $48.30M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 14 | Point72 Asset Management ✦ | 588.21K | Nuevo | $43.54M | 0.1% | New | 1 | SEC ↗ |
| 15 | Soros Fund Management ✦ | 250.00K | -16.7% | $18.51M | 0.5% | ▼ Trim | 2 | SEC ↗ |
| 16 | Millennium Management ✦ | 228.17K | -80.0% | $16.89M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 208.89K | +43.5% | $15.46M | 0.0% | ▲ Add | 3 | SEC ↗ ×5 |
| 18 | Two Sigma Investments ✦ | 125.03K | +67.7% | $9.26M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 19 | Bridgewater Associates ✦ | 108.28K | -34.5% | $8.02M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 20 | Arrowstreet Capital ✦ | 45.99K | -48.8% | $3.40M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 21 | Gotham Asset Management ✦ | 16.42K | +105.8% | $1.22M | 0.0% | ▲ Add | 3 | SEC ↗ |
"Their weight" = la participación de la posición en el valor de renta variable 13F reportado por ese manager: la medida de convicción. ✦ = manager curado.
Nuevos compradores
| Point72 Asset Management | $43.54M | 0.1% |
Posición cerrada
| Sin salidas rastreadas este trimestre. |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 4 tenedores, 229.24K acciones, $319,498 declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué más suelen tener los titulares rastreados de este valor: recuentos de titularidad compartida, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Officer · 619 acc. · $53,017
Officer · 619 acc. · $54,169
Officer · 544 acc. · $49,534
Officer · 2.64K acc. · $237,907
Officer · 1.24K acc. · $113,417
Officer · 1.15K acc. · $105,893
Officer · 30.65K acc. · $2.79M
Officer · 619 acc. · $56,967
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología